Skip to main content
. 2013 Nov 9;8:264. doi: 10.1186/1748-717X-8-264

Table 2.

Comparison of PTV doses calculated from PVP, HAP and non-enhanced CTs

  Dp Da Dn P(p,a,n)* (Dn-Dp)/Dn(%) P(p,n)# (Dn-Da)/Dn(%) P(a,n)# (Da-Dp)/Dn(%) P(p,a)#
3D-CRT
  
  
  
  
  
  
  
  
  
  
CI
 0.84 ± 0.07
 0.83 ± 0.07
 0.83 ± 0.07
 0.116
 -1.15 ± 2.44
 -
 -0.49 ± 1.72
 -
 -0.66 ± 1.00
 -
HI
 0.17 ± 0.02
 0.17 ± 0.02
 0.17 ± 0.02
 0.117
 1.04 ± 4.84
 -
 -0.50 ± 5.77
 -
 1.54 ± 4.29
 -
D98% (Gy)
 46.83 ± 0.28
 47.09 ± 0.41
 47.36 ± 0.46
 0.000
 1.12 ± 0.78
 0.000
 0.56 ± 0.51
 0.000
 0.56 ± 0.58
 0.000
D95% (Gy)
 48.09 ± 0.06
 48.36 ± 0.29
 48.62 ± 0.40
 0.000
 1.10 ± 0.76
 0.000
 0.54 ± 0.58
 0.000
 0.56 ± 0.56
 0.000
D50% (Gy)
 53.17 ± 0.52
 53.52 ± 0.57
 53.83 ± 0.75
 0.000
 1.23 ± 0.81
 0.000
 0.58 ± 0.54
 0.000
 0.64 ± 0.56
 0.000
D2% (Gy)
 55.63 ± 1.14
 56.09 ± 1.28
 56.39 ± 1.43
 0.000
 1.33 ± 1.21
 0.000
 0.53 ± 1.09
 0.000
 0.81 ± 0.93
 0.000
IMRT
  
  
  
  
  
  
  
  
  
  
CI
 0.85 ± 0.04
 0.82 ± 0.06
 0.79 ± 0.09
 0.000
 -8.60 ± 9.78
 0.000
 -4.34 ± 6.09
 0.000
 -4.25 ± 5.84
 0.000
HI
 0.05 ± 0.01
 0.06 ± 0.01
 0.06 ± 0.01
 0.040
 4.82 ± 8.30
 0.006
 2.58 ± 5.74
 0.070
 2.24 ± 5.70
 0.111
D98% (Gy)
 47.60 ± 0.20
 47.85 ± 0.30
 48.06 ± 0.45
 0.000
 0.94 ± 0.68
 0.000
 0.43 ± 0.49
 0.000
 0.51 ± 0.43
 0.000
D95% (Gy)
 48.05 ± 0.08
 48.31 ± 0.23
 48.54 ± 0.35
 0.000
 1.01 ± 0.72
 0.000
 0.46 ± 0.50
 0.000
 0.55 ± 0.51
 0.000
D50% (Gy)
 49.24 ± 0.30
 49.54 ± 0.43
 49.80 ± 0.48
 0.000
 1.11 ± 0.83
 0.000
 0.52 ± 0.62
 0.000
 0.59 ± 0.53
 0.000
D2% (Gy)
 50.28 ± 0.45
 50.61 ± 0.51
 50.91 ± 0.60
 0.000
 1.23 ± 0.99
 0.000
 0.59 ± 0.74
 0.000
 0.64 ± 0.66
 0.000
VMAT
  
  
  
  
  
  
  
  
  
  
CI
 0.81 ± 0.08
 0.79 ± 0.08
 0.78 ± 0.10
 0.000
 -4.93 ± 6.74
 0.000
 -2.38 ± 4.89
 0.002
 -2.54 ± 2.91
 0.000
HI
 0.07 ± 0.02
 0.08 ± 0.02
 0.08 ± 0.02
 0.137
 1.92 ± 6.65
 -
 -0.51 ± 4.73
 -
 2.43 ± 4.11
 -
D98% (Gy)
 47.45 ± 0.23
 47.67 ± 0.32
 47.89 ± 0.47
 0.000
 0.90 ± 0.64
 0.000
 0.45 ± 0.45
 0.000
 0.45 ± 0.38
 0.000
D95% (Gy)
 48.06 ± 0.04
 48.28 ± 0.21
 48.51 ± 0.31
 0.000
 0.93 ± 0.66
 0.000
 0.47 ± 0.42
 0.000
 0.46 ± 0.44
 0.000
D50% (Gy)
 49.98 ± 0.41
 50.27 ± 0.51
 50.52 ± 0.51
 0.000
 1.06 ± 0.79
 0.000
 0.49 ± 0.51
 0.000
 0.58 ± 0.52
 0.000
D2% (Gy) 51.19 ± 0.62 51.54 ± 0.76 51.78 ± 0.80 0.000 1.13 ± 0.87 0.000 0.46 ± 0.53 0.000 0.68 ± 0.59 0.000

Abbrevations: PVP, portal venous phase; HAP, hepatic arterial phase. Dp, Da and Dn were the dose calculated from portal venous phase, hepatic arterial phase and non-enhanced phase CTs respectively. 98%, 95%, 50% and 2%, were the minimum absorbed dose that covers 98%, 95%, 50% and 2% of the volume of the PTV respectively. CI, the conformity index; HI, the heterogeneity index. *, Friedman test; #, Wilcoxon signed ranks test.